CDH1 and gastric cancer: Patients with metastatic HDGC typically receive the same, largely ineffective chemotherapies as patients with sporadic gastric cancer; however, HDGC patients experience inferior outcomes to sporadic gastric cancer or gastric cancer with non-pathogenic CDH1 mutations [10, 11].